Program
coprelotamab
Also written as “GB221”, “GB221,2 mg/kg” and “GB221,6 mg/kg”.
Its studies are mostly in Breast Neoplasms · Spinal Muscular Atrophies of Childhood, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Edding Genor Group | 40 open or running | phase 3since Nov 13, 2019 | Nov 12, 2019 | none ahead |
| Gemma Biotherapeutics | 11 open or running | phase 2since May 30, 2025 | May 30, 2025 | Dec 2028phase 2 · NCT07070999 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2019First study: phase 1 study in Breast NeoplasmsNew to Edding Genor GroupEdding Genor Group · NCT04175171 · 32 enrolled · Australia
- Nov 12, 2019Phase 2 study in HER2-positive Breast CancerEdding Genor Group · NCT04170595 · 132 enrolled · China
- Nov 13, 2019Phase 3 study in HER-2-positive Advanced Breast CancerEdding Genor Group · NCT04164615 · 336 enrolled · China
- Mar 2, 2021Phase 1 study in Breast NeoplasmsEdding Genor Group · NCT04905667 · 87 enrolled · China
- May 30, 2025Gemma Biotherapeutics's first study: phase 2 study in Spinal Muscular Atrophies of ChildhoodNew to Gemma BiotherapeuticsGemma Biotherapeutics · NCT07070999 · 22 planned · Brazil
Ahead
- Dec 2028Primary completion: phase 2 study in Spinal Muscular Atrophies of ChildhoodGemma Biotherapeutics · NCT07070999
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07070999Spinal Muscular Atrophies of Childhood · Brazil | 2 | Recruiting | Gemma Biotherapeutics | Dec 2028 | 22 |
| NCT04905667Breast Neoplasms · China | 1 | Completed | Edding Genor Group | Sep 8, 2020 | 87 |
| NCT04164615HER-2-positive Advanced Breast Cancer · China | 3 | UNKNOWN | Edding Genor Group | Jul 2020 | 336 |
| NCT04175171Breast Neoplasms · Australia | 1 | Completed | Edding Genor Group | Jan 8, 2012 | 32 |
| NCT04170595HER2-positive Breast Cancer · China | 2 | UNKNOWN | Edding Genor Group | Dec 2021 | 132 |
How it is read
Names in the registry
- “GB221”, 3 entries
- “GB221,2 mg/kg”, 1 entry
- “GB221,6 mg/kg”, 1 entry
- “GB221,8mg/kg”, 1 entry
- “GB221:2mg/kg and Capecitabi:1000mg/kg”, 1 entry
Codes read as this program: GB221.
Conditions, from the studies’ own filings
- Breast Neoplasms, 4 studies
- Spinal Muscular Atrophies of Childhood, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.